Skip to main content
TipRanks
Go Ultimate75% OFF

Diversified Healthcare Trust (DHC) AI Stock Analysis

626 Followers
DHC

Diversified Healthcare Trust

(NASDAQ:DHC)

Select Model
Rating:52Neutral
Price Target:$7.50â–²(5.63% Upside)
Action:reiterated
Date:11/04/26

The score is held back primarily by weak financial performance (declining TTM revenue, ongoing net losses, negative free cash flow, and still-elevated leverage). Offsetting this, earnings-call commentary was constructive with raised SHOP NOI guidance, strong NOI/EBITDAre growth, and improving liquidity/credit metrics. Technicals remain soft with the stock trading below key moving averages, while valuation is supported by an extremely high dividend yield but constrained by a negative (non-meaningful) P/E.

Positive Factors
SHOP operating momentumSHOP's 50.4% year-over-year NOI growth, higher occupancy and wider margin indicate improving performance in a core segment. If sustained, this combination can strengthen recurring property cash flow, support earnings recovery, and improve the portfolio's operating trajectory over the next several quarters.
Negative Factors
Persistent unprofitability and weak cash conversionDeclining revenue, ongoing net losses, and negative free cash flow show that property-level earnings have not yet translated into durable corporate profitability. Continued cash shortfalls could constrain reinvestment, debt reduction, and distributions unless operating improvements become more consistent.

Diversified Healthcare Trust Key Performance Indicators (KPIs)

Revenue by SegmentHow revenue is split across different business segments and property types, showing which areas drive the top line. Useful for spotting reliance on specific markets, tenants, or service lines and for assessing sensitivity to occupancy trends, payer mix, and contract or reimbursement changes.

$0.00$100.00M$200.00M$300.00M$400.00MMar 21Jun 21Sep 21Dec 21Mar 22Jun 22Sep 22Dec 22Mar 23Jun 23Sep 23Dec 23Mar 24Jun 24Sep 24Dec 24Mar 25Jun 25Sep 25Dec 25Mar 26Jun 26Sep 26
Chart Insights

SHOP is the clear growth engine, driven by rate and occupancy gains plus expense synergies, which explains most of the revenue momentum and underpins management’s confidence; note Q2 benefited from a ~$1.5M one‑time expense reversal and SHOP occupancy guidance was trimmed, so near‑term outperformance may include nonrecurring upside. Medical Office & Life Science is the structural underperformer with recent leasing losses and known vacates that will pressure NOI, while modest balance‑sheet improvement cushions risk but leverage remains a watch item.

Data provided by:The Fly

Diversified Healthcare Trust (DHC) vs. SPDR S&P 500 ETF (SPY)

-25%0%25%50%75%100%125%DHC+58.31%SPY+13.31%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
$1.75B
Dividend Yield
0.55%
Average Volume (3M)
1.77M
Price to Earnings (P/E)
-11.3
Beta (1Y)
0.31
Revenue Growth
-3.82%
EPS Growth
56.90%
Country
US
Employees
600
Sector
Real Estate
Sector Strength
65
Industry
REIT - Healthcare Facilities

Diversified Healthcare Trust Business Overview & Revenue Model

Company Description

Diversified Healthcare Trust (DHC) operates as a real estate investment trust (REIT) specializing in healthcare properties. Its extensive portfolio comprises medical office buildings, life science facilities, senior living communities, and wellness c...

How the Company Makes Money

DHC makes money primarily through real estate rental and related property-level income generated by its portfolio. Key revenue streams generally include: (1) Lease revenue from healthcare properties (e.g., medical office buildings and similar assets)...

Diversified Healthcare Trust Earnings Call Summary

Earnings Call Date:Nov 02, 2026(Q3-2026)|% Change Since:-8.27%|Next Earnings Date:Mar 01, 2027
Earnings Call SentimentPositive

The call was predominantly positive, led by strong year-over-year growth in Adjusted EBITDAre, consolidated NOI, and SHOP NOI; improved occupancy and margins; raised SHOP NOI guidance; lower recurring capital expenditure guidance; portfolio optimization initiatives; and improving liquidity and credit metrics. The main challenges were medical office and life science vacancies, a sequential SHOP NOI decline caused by stated one-time and seasonal items, temporary use of occupancy concessions, and lower normalized FFO per-share guidance due to the revised incentive fee presentation.

Positive Updates

Strong Third-Quarter Financial Performance
Normalized FFO was $30.7 million, or $0.13 per share, and Adjusted EBITDAre was $73.4 million, an increase of 28.4% year over year. On the comparable basis including estimated incentive management fees, normalized FFO increased from $0.02 per share a year ago and from $0.12 per share in the second quarter.

Negative Updates

Medical Office and Life Science NOI Decline
Same property cash basis NOI in the medical office and life science portfolio decreased 1.6% year over year to $22.9 million, primarily reflecting a previously disclosed tenant vacancy.

Company Guidance

For full year 2026, same property SHOP NOI guidance was raised by $5 million at the midpoint to $190 million to $200 million, with expected operating expense growth of 2.3% compared with 2.5% previously, average monthly rate growth of 5.6% up from 5.5%, occupancy growth unchanged at 200 basis points, and revenue growth of 6.3%; updated guidance is $312 million to $328 million of same property NOI, Adjusted EBITDAre of $276 million to $291 million, normalized FFO of $111 million to $126 million or $0.46 to $0.52 per share, and recurring capital expenditures of $90 million to $105 million, a reduction of $10 million at the midpoint, with estimated incentive management fees of $29.3 million or $0.12 per share included; fourth quarter results will include a full quarter of Ensign rent contributing approximately $2 million of cash NOI, recurring SHOP CapEx could decrease a little bit into 2027 and 2028 with a target closer to $3 thousand per unit, and redevelopment projects are all 2027 starts, with the swinging of hammers expected to commence next year and some projects beginning toward the back half of the year.

Diversified Healthcare Trust Financial Statement Overview

Summary

Fundamentals remain pressured despite some stabilization. Revenue is down sharply in the latest TTM, net income is still persistently negative (TTM net margin ~-10%), and free cash flow is negative (TTM ~-$46.8M). Offsetting positives include a solid TTM EBITDA margin (~21%), a swing back to positive operating cash flow (~$54M), and reduced total debt versus 2021, though leverage remains elevated and equity has eroded.

Income Statement

32Negative

Balance Sheet

46Neutral

Cash Flow

41Neutral
Financial statement breakdown
BreakdownTTMDec 2025Dec 2024Dec 2023Dec 2022Dec 2021
Income Statement
Total Revenue1.48B1.54B1.50B1.41B1.28B1.38B
Gross Profit-61.28M-245.33M256.38M225.30M174.50M291.40M
EBITDA304.84M182.28M229.96M198.93M427.79M701.03M
Net Income-152.14M-285.89M-370.25M-293.57M-15.77M174.51M
Balance Sheet
Total Assets4.19B4.36B5.14B5.45B6.00B6.62B
Cash, Cash Equivalents and Short-Term Investments110.66M121.80M144.58M245.94M658.07M634.85M
Total Debt2.42B2.42B2.91B2.82B3.08B3.68B
Total Liabilities2.66B2.70B3.18B3.11B3.36B3.96B
Stockholders Equity1.53B1.67B1.96B2.34B2.64B2.66B
Cash Flow
Free Cash Flow-46.78M-19.62M112.22M10.48M-40.35M-63.32M
Operating Cash Flow54.01M-19.62M112.22M10.48M-40.35M-63.32M
Investing Cash Flow155.38M483.57M-187.02M-202.11M387.71M242.70M
Financing Cash Flow-288.06M-492.01M-22.31M-249.71M-676.00M746.72M

Diversified Healthcare Trust Technical Analysis

Technical Analysis SentimentNegative
Last Price7.10

Price Trends

50DMA7.66Negative
100DMA8.15Negative
200DMA7.84Negative

Market Momentum

MACD-0.15Positive
RSI36.78Neutral
STOCH47.02Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For DHC, the sentiment is Negative. The current price of 7.10 is below the 20-day moving average (MA) of 7.53, below the 50-day MA of 7.66, and below the 200-day MA of 7.84, indicating a bearish trend. The MACD of -0.15 indicates Positive momentum. The RSI at 36.78 is Neutral, neither overbought nor oversold. The STOCH value of 47.02 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for DHC.

Diversified Healthcare Trust Risk Analysis

Diversified Healthcare Trust disclosed 56 risk factors in its most recent earnings report. Diversified Healthcare Trust reported the most risks in the "Finance & Corporate" category.

Higher RiskSector Avg.Lower RiskFinance & CorporateTech & InnovationLegal & RegulatoryProductionAbility to SellMacro & Political
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy

Latest Risks Added

3 New Risks
1.RMR is incorporating artificial intelligence, or AI, into some of its business workflows and processes, and challenges with properly managing its use could result in reputational harm, competitive harm, legal liability, and increased regulatory costs and adversely affect our results of operations.Q4, 2024
2.We may not realize the benefits we expect from our ownership interest in AlerisLife.Q4, 2023
3.We have a substantial amount of debt and are subject to risks related to our debt, including our ability to refinance maturing debt and the cost of any such refinanced debt.Q4, 2023

Diversified Healthcare Trust Peers Comparison

Overall Rating

UnderperformOutperform
Sector (65)

Financial Indicators

DHC against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
SBRASBRA72Outperform$5.35B73.002.55%5.87%21.20%-61.51%
VTRVTR70Outperform$48.04B164.671.89%2.29%22.13%0.00%
WELLWELL70Outperform$179.34B118.103.23%1.30%39.11%-140.16%
Sector *65Neutral$2.17B12.193.79%4.94%3.15%1.96%
DOCDOC63Neutral$14.12B37.005.00%6.11%9.42%―
HRHR58Neutral$6.54B-135.77-1.04%4.97%-6.28%77.63%
DHCDHC52Neutral$1.75B-11.32-9.51%0.55%-3.82%56.90%

* Real Estate Sector Average

Performance Comparison

0%25%50%75%100%DHCDOCWELLSBRAVTRHRDec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
DHC and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
DHCDiversified Healthcare Trust7.102.5555.91%
DOCHealthpeak Properties, Inc.19.843.2719.71%
WELLWelltower, Inc.244.6549.1525.14%
SBRASabra Healthcare Reit20.352.6214.75%
VTRVentas Inc88.8810.9414.04%
HRHealthcare Realty Trust Incorporated19.321.9611.27%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Nov 04, 2026